Ondansetrom Generis (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetrom Generis, is a 5-HT3 receptor antagonist presented as a 4 mg oral tablet for systemic use. It helps prevent nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adult patients. GNH USA supplies Ondansetrom Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Ondansetrom Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: reduces the incidence and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting: provides prophylactic control for patients receiving moderate to high dose radiation. - Post‑operative nausea and vomiting: lowers the risk of early postoperative emesis following general anesthesia. - Pregnancy‑related hyperemesis gravidarum (off‑label in some regions): may be used when benefits outweigh risks. - Anticipatory nausea: helps patients who have learned to associate treatment with nausea.

Ondansetron is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel slowing. - Diarrhoea: transient loose stools. - Fatigue: feeling of tiredness. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with IV use. - Severe hypersensitivity: rash, angio‑edema, anaphylaxis. - Serotonin syndrome: when combined with other serotonergic agents. - Hepatic enzyme elevation: abnormal liver function tests. - Neuroleptic malignant‑like syndrome: rare extrapyramidal signs.

When prescribing Ondansetrom Generis, clinicians should consider several safety aspects.

- Cardiac monitoring: assess baseline ECG in patients with known QT prolongation. - Drug interactions: review concomitant medications that affect cardiac repolarisation. - Renal impairment: adjust dose in severe renal dysfunction. - Hepatic impairment: use caution in patients with significant liver disease. - Pregnancy and lactation: weigh benefits against potential risks. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture and direct sunlight.

Ondansetron can interact with several medicines, altering its safety profile or efficacy.

Major Interactions (Avoid): - Class I anti‑arrhythmics (e.g., quinidine, procainamide): increase risk of QT prolongation. - Certain azole antifungals (ketoconazole, itraconazole): potentiate cardiac effects. - Serotonergic agents (SSRIs, MAOIs, tramadol): raise the possibility of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, grapefruit juice): may raise ondansetron plasma levels. - CYP2D6 substrates (e.g., metoprolol, codeine): modestly increased exposure. - Diuretics (e.g., furosemide): can exacerbate electrolyte disturbances that affect QT interval.